What they were paid
AN2 Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $59,000 | $0 | $20,393 | — | $79,393 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AN2 Therapeutics, Inc. DEF 14A filed April 22, 2026, accession 0001193125-26-170314, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025AN2 Therapeutics pays directors a $40,000 cash retainer and $104,546 in Options.
Committees
FY2025 · as the proxy prints themAudit (Chair) · Nominating/Governance
The rest of the AN2 Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Eric Easom | Chair of the Board | $0 |
| Gilbert Lynn Marks, M.D | Independent Director | $57,904 |
| Joseph Zakrzewski | Independent Director | $71,893 |
| Kabeer Aziz | Independent Director | $57,904 |
| Margaret FitzPatrick | Lead Independent Director | $89,393 |
| Melvin Spigelman, M.D | Independent Director | $67,893 |
| Patricia Martin | Independent Director | $72,240 |
| Rob Readnour, Ph.D | Independent Director | $68,393 |
The full AN2 Therapeutics compensation record
free company briefThis page is one director within AN2 Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat